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Abstract: Chronic obstructive pulmonary disease (COPD) is a complex chronic inﬂ  ammatory 
disease involving a wide variety of cells and inﬂ  ammatory mediators. The most important etio-
logical factor in the development of this disease is cigarette smoking. Much of the research into 
the mechanisms of COPD has been concerned with the induction of inﬂ  ammation and the role 
of neutrophils and macrophages in the pathophysiology of the disease. The possible contribution 
of the epithelium to the development of COPD has only recently become apparent and remains 
unclear. In this article we review research into the effect of cigarette smoke on the pulmonary 
epithelium with particular emphasis on oxidative stress, proteolytic load, pro-inﬂ  ammatory 
cytokine and chemokine proﬁ  le and epithelial secretions. In addition, we have also reviewed 
how cigarette smoke may affect epithelial damage and repair processes.
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Introduction
COPD is a major cause of morbidity and mortality and is the fourth most common cause 
of death in the USA. It is estimated that over one million individuals in the UK, 6% of 
men and 4% of women, suffer from COPD (Barnes 1998) with some 30,000 deaths per 
year. The global initiative for chronic obstructive lung disease (GOLD) deﬁ  nes COPD 
as a “disease state characterized by airﬂ  ow limitation that is not fully reversible. The 
airﬂ  ow limitation is usually both progressive and associated with an abnormal inﬂ  am-
matory response of the lungs to noxious particles or gases” (Pauwels et al 2001).
Smoking is the most important causative factor in the development of COPD. 
COPD is the culmination of three pathological disorders, chronic bronchitis, small 
airways disease and emphysema, which can exist separately or in combination. His-
torically, inﬁ  ltrating leukocytes were thought to be central to the pathology whilst the 
epithelium was believed to be merely an observer and target of the damage. However, 
recent research shows that the epithelium is in fact a rich source of molecules involved 
in modulating inﬂ  ammation and lung defense mechanisms.
Airway epithelial structure
The airway epithelium is one of the ﬁ  rst targets of cigarette smoke. The cellular proﬁ  le 
and function of the airway epithelium adapts to protect the lung from the effects of 
smoking and the inﬂ  ammatory response but, in smokers who develop COPD, these 
changes contribute to irreversible pathological changes in lung structure and function. 
The complex pathology of COPD involves distinct cellular responses of different 
regions of the respiratory tract to cigarette smoke which in turn reﬂ  ects the need for 
the airways to respond to both acute and chronic exposure.
Large airways
The epithelial layer of the cartilaginous airways comprises a diverse array of pseu-
dostratiﬁ  ed columnar cells. The ciliated, serous, Clara and goblet cells are essential International Journal of COPD 2007:2(4) 410
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to mucociliary defense. In the trachea the ciliated cells pre-
dominate, making up as much as 60% of the total cell number 
(Wanner et al 1996) and amongst these, approximately 20% 
are mucus secreting goblet cells (Lozewicz et al 1990). By 
the 5th generation, ciliated cell numbers fall to approximately 
15% and in further generations, ciliated and goblet cell num-
ber diminish as they are replaced by serous and Clara cells. 
The sub-mucosal region of the cartilaginous airways contains 
glands that are forty times more frequent than goblet cells 
and release sero-mucus secretions.
Chronic bronchitis is deﬁ  ned as “the presence of chronic 
cough and recurrent increases in bronchial secretions suf-
ﬁ  cient to cause expectoration. The secretions are present 
on most days for a minimum of three months a year, for at 
least two successive years, and cannot be attributed to other 
pulmonary or cardiac causes” (Siafakas et al 1995). Cigarette 
smoke induces epithelial changes associated with develop-
ment of bronchitis which may or may not be associated with 
COPD, which depends on the degree of epithelial inﬂ  amma-
tion (Maestrelli et al 2001; Vestbo and Hogg 2006). There is 
goblet cell hyperplasia and submucosal gland hypertrophy 
associated with loss of ciliated epithelial cell numbers and 
function leading to reduced mucociliary clearance and mucus 
plug formation. Increased numbers of goblet cells are also 
found in the small bronchi and bronchioles, where there 
are normally very few (Cosio et al 1980). Under scanning 
electron microscopy a continuous layer of mucus can be seen 
covering the airways, unlike in healthy subjects where it is 
only seen in discrete patches (Jeffery 1998).
Small airways
The small airways are a signiﬁ  cant site of cigarette smoke-
induced pathology. Hogg and colleagues observed that 
non-cartilaginous airways of 2 millimeters or less in diam-
eter provide only a small part of the total airway resistance, 
approximately 25%, in healthy patients, whereas in those 
with COPD it becomes the principal site of increased airway 
resistance (Hogg et al 1968). Thus, in smokers with mild 
emphysema, despite no change in total airway resistance, 
there was a four fold increase in peripheral airway resistance. 
More severe cases of emphysema displayed an increase in 
total airway resistance due almost entirely to the increase in 
the peripheral airway component. Even though there may 
be minimal signs of emphysema, the peripheral airways of 
smokers exhibit a signiﬁ  cantly greater number of bronchi-
oles with a diameter less than 0.4mm (Cosio et al 1980). 
Studies of young smokers (Niewoehner et al 1974) showed 
denuded epithelium in peripheral bronchioles associated 
with an increased number of inﬂ  ammatory cells. In addition 
to inﬂ  ammatory cell inﬁ  ltration (Saetta 1998), metaplasia of 
goblet cells (Saetta et al 2000) and ﬁ  brosis (Vlahovic et al 
1999) have been described, resulting in increased thickness 
of walls, which all contribute to increased airways resistance 
due to airways obstruction. The appearance of (usually 
absent) goblet cells in the bronchioles is a primary charac-
teristic of this disease, and leads to production of mucus at 
a site in the lung where there is no mucociliary transport to 
clear the accumulating secretions. This increase in mucus 
provides a prime site for chronic bacterial colonization (Sethi 
2000), further aggravating the condition.
Respiratory units
The alveolar airspaces form a complex network of alveolar 
ducts tightly associated with a rich capillary network. The 
alveolar epithelial layer consists of two cell types, the type 
1 (AT1) and type 2 (AT2) epithelial cells. These cells form 
tight junctions and lie on a thin fused basement membrane 
that is shared with, and separates them from, the capillary 
endothelium. The AT2 cell makes up the majority of the 
alveolar epithelial cells by number, but only a fraction of the 
surface area, as only a small projection on the apical side of 
the cell is apparent between the attenuated AT1 cells. Thus, 
although there are twice as many AT2 cells, the AT1 cells 
cover over 90% of the alveolar surface.
AT2 cells are the secretory cells of the alveolus, where 
they synthesize and secrete surfactant (Frerking et al 2001) to 
maintain surface tension and prevent alveolar collapse, as well 
as producing defense molecules such as collectins and anti-
oxidants. The AT2 cell is also a stem cell. Following damage 
to the alveolar epithelium, AT2 cells proliferate and migrate 
into the damaged area where they can differentiate into AT1 
cells and restore the tight barrier to protect the interstitium 
and capillary bed from environmental materials (Kim et al 
1997). AT1 cells are highly attenuated, ﬂ  attened epithelial cells 
which provide a large surface area with a thin gas-permeable 
barrier of approximately 0.2μm in depth to allow rapid, free 
gas exchange between the alveolar airspace and the underlying 
capillary network. Relatively little is known about AT1 cells 
(especially human) as it is only recently that methods have 
been established to isolate these cells and identify speciﬁ  c 
AT1 cell markers so that these cells can be recognised and 
investigated in vivo and in vitro (McElroy and Kasper 2004). 
AT1 cells have been described as terminally differentiated, but 
as their turnover rate is 40-120 days it is difﬁ  cult to observe 
or monitor AT1 cell division (Williams 2003), and in vitro 
studies suggest that AT1 cells may sometimes revert to the International Journal of COPD 2007:2(4) 411
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AT2 cell phenotype, although there is as yet no evidence that 
this occurs in vivo (Borok et al 1998).
It is at this site where the third component of COPD, 
emphysema, occurs. It is a destructive disease described as 
”a loss of lung elasticity and abnormal enlargement of the air 
spaces distal to the terminal bronchioles, with destruction of the 
alveolar walls and capillary beds” (Porth 2005). An early event 
is the destruction of the elastic ﬁ  bers that provide the natural 
recoil of the lung, leading to deformation of the alveoli and 
respiratory bronchioles (Saetta et al 1985). This in turn results 
in a decreased number of functional alveoli and leads to one 
symptom that is often a strong indicator of emphysema, short-
ness of breath. Two subtypes of emphysema exist. The ﬁ  rst, 
centriacinar emphysema, occurs in smokers and is conﬁ  ned to 
the apical regions of the lung. It is characterized by destruction 
of the central zone of the acinus leading to enlarged respira-
tory bronchioles. The second, panacinar emphysema, involves 
destruction of the whole of the acinus almost uniformly and 
tends to affect the lower lobes of the lung more than the upper 
lobes (Snider 1992). Panacinar emphysema occurs in smok-
ers with alpha 1-antitrypsin deﬁ  ciency but is also present in 
smokers with normal alpha 1-antitrypsin levels and advanced 
emphysema.
Epithelial antioxidants
Non-enzymatic antioxidants
The lung employs a number of enzymatic and non-enzymatic 
antioxidant mechanisms to neutralize the deleterious effects 
of ROS. Numerous non-enzymatic antioxidants are present 
in the lung lining ﬂ  uid, including uric acid, ascorbic acid, 
glutathione and α-tocopherol. Of these, glutathione (GSH) is 
synthesized locally in the lungs, is critical to the protection of 
the airspaces and the intracellular compartment of the airway 
epithelium and is found in increased amounts in secretions 
from smokers (Cantin et al 1987). It is a tripeptide consist-
ing of glutamate, cysteine and glycine and contains a thiol 
group which is able to neutralize oxidative activity by acting 
as a target for ROS causing oxidation of the thiol group and 
dimerisation to form GSSG. This dimer can then be reduced 
back to active GSH units by the activity of glutathione reduc-
tase (Figure 1), which is also found both extracellularly, in 
lung lining liquid, and intracellularly. GSH is synthesized 
and released by pulmonary epithelial cells and macrophages 
and the increased levels of GSH in smokers’ lung secretions 
may be due to smoking-associated increases in glutamate 
cysteine ligase, a rate-limiting enzyme crucial to cellular 
GSH synthesis (Neurohr et al 2003), and hence subsequent 
release. In vitro studies of the A549 adenocarcinoma cell line 
and in vivo studies in rats have shown however, that acute 
exposure to cigarette smoke is associated with a decrease in 
GSH (Rahman et al 1995). This work has been conﬁ  rmed 
in other species where it was hypothesized that the decrease 
in glutathione levels may be due to decreased synthesis or 
conjugation with electrophilic cigarette smoke components 
(Joshi et al 1988). Why there is a disparity between the effect 
of acute and chronic exposure to cigarette smoke is not fully 
understood. Increased extracellular GSH in chronic smokers 
and COPD subjects may reﬂ  ect active release of intracellular 
GSH or release due to increased cell permeability and/or cell 
death. Since epithelial cells synthesize and release signiﬁ  cant 
quantities of GSH, they are an important source of GSH, play-
ing a role in antioxidant defense against cigarette smoke.
Enzymatic antioxidants
In addition to GSH, the respiratory epithelium produces 
a number of enzymes with powerful antioxidant activity, 
including the superoxide dismutases (SOD), catalase and 
enzymes associated with glutathione regulation (Bowler, 
Barnes, and Crapo 2004). Of the superoxide dismutases, cop-
per zinc SOD (CuZnSOD) and extracellular SOD (ECSOD) 
are expressed throughout the respiratory tract epithelium, 
whereas manganese SOD (MnSOD) is mainly expressed by 
the AT2 cells (Dobashi et al 1993). This class of enzyme 
is the only one to have activity against superoxide radicals 
(Figure 1) produced by activated leukocytes and studies in 
humans and animals have shown that SOD expression is 
sensitive to cigarette smoke exposure. Studies in rats have 
revealed that MnSOD expression is rapidly and transiently 
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Figure 1 (A) Enzymatic clearance of reactive oxygen species. Superoxide anions 
undergo dismutation by superoxide dismutase (SOD) leading to the generation of 
hydrogen peroxide. This in turn is processed by catalase and glutathione peroxidase 
(GPx). (B) Reduced glutathione (GSH) is regenerated from its oxidized form (GSSG), 
using NADPH, by glutathione reductase (GRx).International Journal of COPD 2007:2(4) 412
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up-regulated following exposure to cigarette smoke (Stringer 
et al 2004). Its expression is also found to be up-regulated 
by 30%–50% in the lungs of smokers, in particular in the 
AT2 cell (Harju et al 2004), suggesting an important role 
combating the oxidative effects of cigarette smoke.
Catalase, glutathione peroxidase (GPx), glutathione 
reductase and glutamate cysteine ligase are all important 
enzymes in the clearance of hydrogen peroxide (Figure 1) and 
lipid peroxides from the lung and are found to be expressed 
throughout the respiratory tract epithelium (Hackett et al 
2003). Catalase is most highly expressed in AT2 cells and 
is widely considered to be the most important enzyme in 
the clearance of hydrogen peroxide (Farioli-Vecchioli et al 
2001). Studies of human lung tissue have shown that, in the 
COPD lung, mRNA expression of catalase is signiﬁ  cantly 
reduced compared to non-smokers’ lung (Tomaki et al). Of 
the enzymes involved in glutathione regulation, GPx has been 
the most actively researched. However, how cigarette smoke 
affects GPx remains unclear. Studies of human and animal 
tissue have shown that the primary sites of GPx production 
are the epithelium and alveolar macrophage (Avissar et al 
1996; Comhair et al 2001). Studies using macrophages and 
epithelial cells obtained by BAL and bronchial brushings 
from humans have shown that smokers have increased levels 
of mRNA for GPx (Comhair et al 2001; Hackett et al 2003). 
Conversely, in gene micro-array studies of lung tissue from 
subjects with advanced emphysema, GPx expression was 
found to be down-regulated (Golpon et al 2004). This differ-
ence in results may reﬂ  ect alterations occurring in the lung 
tissue structure and cell proﬁ  le during disease progression 
where GPx is important for maintaining antioxidant status but 
where loss of epithelial structure and/or function, eg during 
emphysema, crucially limits GPx.
Thus, the pulmonary epithelium is a signiﬁ  cant source 
of pulmonary antioxidants, which may be stimulated or 
inhibited, acutely or chronically, depending on the smok-
ing status, history and lung pathology of each individual. 
It seems likely that, in susceptible individuals, antioxidant 
defenses may initially be effective but may ultimately be 
overwhelmed leading to oxidative stress-induced inﬂ  amma-
tion and tissue damage.
Oxidative stress
Exogenous sources
The lung is constantly exposed to oxidants which may 
either be produced endogenously, by metabolic reactions, or 
derived exogenously, for example, in air pollutants and ciga-
rette smoke. This, coupled with the high oxygen environment 
and large surface area of the lung, means the lung could 
be highly susceptible to injury by reactive oxygen species 
(ROS). It is estimated that there are more than 1014 oxidative 
free radicals per puff of cigarette smoke (Church and Pryor 
1985). As well as the more common short-lived oxidants 
such as the superoxide radical (O2
•-) and nitric oxide (NO), 
there a number of oxidative molecules which can persist in 
the lung for longer periods of time such as tar-semiquinone 
(Pryor and Stone 2007). This oxidant can generate the highly 
potent hydroxyl radical (•OH) and hydrogen peroxide in the 
presence of iron via the Fenton reaction. This is particularly 
important in the smoker’s lung, where there are also elevated 
levels of free iron (Mateos et al 1998).
Cellular sources
In addition to exogenous sources of oxidative stress, activated 
macrophages and neutrophils are known to release high lev-
els of reactive oxygen species, in particular, O2
• -,  hydrogen 
peroxide and •OH (Bowler et al 2004). This, coupled with 
the greater numbers of these cells in the lungs of smokers, 
further compounds the situation. In vivo studies have shown 
that cigarette smoking induces a transient increase in neu-
trophil sequestration in the lungs (van der Vaart et al 2005). 
Further in vitro studies suggest that this increase in neutro-
phil numbers may be, at least in part, oxidant-dependent 
as cigarette smoke-induced oxidative stress in neutrophils 
leads to polymerization of F actin ﬁ  laments in the cytosol 
which lead to a decrease in the deformability of the cells 
(Drost et al 1992), which consequently become trapped in 
the capillaries prior to migrating into the airway lumen. In 
addition, epithelial cells, as well as leukocytes, may generate 
extracellular ROS via NADPH oxidase. Such ROS can play 
an important role in gene transcription.
Role of oxidants in gene transcription
The airway epithelium is one of the ﬁ  rst cellular targets of ciga-
rette smoke. ROS cause lipid peroxidation, which can impair 
cellular function in a number of ways including disruption of 
the cellular membrane and inactivation of membrane-bound 
receptors and enzymes (Rahman 2005). A number of products 
of oxidative stress, including those of lipid peroxidation, have 
been shown to inactivate histone deacetylase-2, an enzyme 
which is integral to the regulation of pro-inﬂ  ammatory gene 
transcription (Rahman et al 2004). HDACs are a family of 
enzymes which, along with histone acetylases, control gene 
transcription. Acetylation of lysine residues on histones 
neutralizes their charge, causing the chromatin to unwind 
and thus increase accessibility for transcription factors and International Journal of COPD 2007:2(4) 413
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subsequent up-regulation of gene transcription. Conversely, 
deacetylation of lysine residues on the histone causes con-
formational changes which allow the chromatin structure to 
close and become inaccessible to transcription factors (Barnes 
et al 2005) thus preventing gene transcription. One of the anti-
inﬂ  ammatory mechanisms of corticosteroids is to up-regulate 
HDAC activity which in turn down regulates transcription 
of pro-inﬂ  ammatory mediators. HDACs may be particularly 
relevant to COPD as oxidative inactivation of HDAC-2 results 
in steroid resistance, a phenomenon well recognised in COPD 
which has made treating the disease extremely difﬁ  cult. The 
activity of HDACs -2, -3, -5 and -8 have all been demonstrated 
to be reduced in COPD subjects (Rahman, Marwick, and 
Kirkham 2004; Ito et al 2005).
Oxidative stress can also activate the redox sensitive 
transcription factors, nuclear factor-kappa B (NF-κB) and 
activator protein-1 (AP-1). NF-κB was the ﬁ  rst transcrip-
tion factor shown to be regulated by oxidative stress. It has 
been demonstrated that a variety of stimuli known to activate 
NF-κB, including interleukin- 1 (IL-1), tumor necrosis factor-α 
(TNF-α), UV irradiation and LPS, also induce a transient 
increase in ROS. This increase in ROS leads to NF-κB being 
released from its inhibitory complex with IκB, allowing it to 
translocate to the nucleus (Schulze-Osthoff et al 1995) where 
it triggers expression of inﬂ  ammatory mediators. In vitro 
studies using the A549 adenocarcinoma and H1299 cell lines 
and primary human bronchial epithelial cells have shown 
that cigarette smoke condensate can induce expression of 
mRNA for a number of cytokines including, most notably, 
IL-6 and CXCL8 (IL-8). This, they showed, correlated with a 
concomitant increase in NF-κB activity (Kode et al 2006) as a 
result of increased oxidative stress. A consequence of cigarette 
smoke-induced activation of epithelial AP-1 is increased mucin 
secretion, addressed in more detail later in this review.
Epithelial antiproteases
Serine protease inhibitors – SERPINs
The association of an increased protease burden with 
development of emphysema was established in the 1960’s 
when it was shown that a deﬁ  ciency in alpha 1-antitrypsin, 
a serpin (SERine Proteinase INhibitor) and the major serum 
neutrophil elastase inhibitor, was associated with early 
onset emphysema (Laurell and Eriksson 1963). However, 
the epithelium is not the major source of pulmonary alpha 
1-antitrypsin (a 54KDa protein synthesized in the liver and 
secreted into the circulation) which is largely serum-derived, 
diffusing into the lung tissue and airways. Until recently, 
alpha 1-antitrypsin was the only antiprotease known to be 
genetically linked to COPD. Interestingly, another serpin, 
SERPINE2, which codes for a thrombin and urokinase 
inhibitor, has recently been associated with development of 
COPD (Zhu et al 2007). This 44 kDa protein is expressed 
by pulmonary epithelium and is up-regulated in emphysema 
(Demeo et al 2006). The antiprotease has not been shown 
to inhibit neutrophil elastase and its exact functional role in 
COPD has not been established; it is possible that its effects 
are unrelated to antiprotease activity.
Low molecular weight inhibitors of serine 
proteases
The pulmonary epithelium is a major site of synthesis and 
release of the low molecular weight serine protease inhibitors, 
secretory leukocyte protease inhibitor (SLPI; also known as 
antileukoprotease or mucus proteinase inhibitor) and elaﬁ  n 
(also known as elastase-speciﬁ  c inhibitor and skin-derived 
antileukoprotease, SKALP). All the secretory cells, includ-
ing goblet cells, serous cells, Clara cells and AT2 cells can 
synthesize and release SLPI and elaﬁ  n. SLPI is 11.7kDa; 
elaﬁ  n (6kDa) is a cleavage product of pre-elaﬁ  n (also called 
trappin-2), which is 9.9kDa. These are both cationic, non-
glycosylated, acid stable, serine proteinase inhibitors that 
are also important in host defense and tissue repair (Tetley 
2006). Both antiproteases are potent, reversible inhibitors of 
neutrophil elastase; SLPI also inhibits cathepsin G, trypsin, 
chymotrypsin and chymase, while elaﬁ  n also inhibits pro-
teinase-3 (Tetley 2006). SLPI is constitutively expressed, 
released at high levels into the lung lumen and is also found 
interstitially, bound to extracellular matrix, due to its cationic 
properties, where it is a very effective inhibitor of matrix-
bound neutrophil elastase (unlike alpha 1-antitrypsin). In 
contrast, epithelial-derived elaﬁ  n is not normally synthesized 
at high levels but it can be up-regulated, for example during 
infection or following corticosteroids, to supplement base-
line antiprotease levels. In vitro studies show that elaﬁ  n is 
synthesized in response to inﬂ  ammatory mediators such as 
cytokines, eg TNF-α, IL-1β (Bingle et al 2001; Sallenave 
2002), as well as lipopolysaccharide (LPS) and, interestingly, 
elaﬁ  n is also up-regulated by neutrophil elastase itself (Reid 
et al 1999), which may be a feedback mechanism. SLPI is 
usually present in lung secretions at higher concentrations 
than elaﬁ  n, but is also upregulated by the same mediators.
SLPI is the most abundant serine protease inhibitor in 
the large and central airway secretions and contributes a 
signiﬁ  cant proportion of the serine protease inhibitory capac-
ity in the respiratory units. Although goblet cell metaplasia 
and hypersecretion leading to increased levels of SLPI might International Journal of COPD 2007:2(4) 414
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be expected during bronchitis, there is an inverse relationship 
between sputum SLPI and increased neutrophil elastase, pos-
sibly due to proteolysis of SLPI or re-location to other lung 
compartments (eg interstitium). Loss of alveolar epithelium 
in emphysema is also likely to reduce absolute levels of 
SLPI and elaﬁ  n. Latent adenoviral infection of bronchial and 
alveolar epithelial cells and elevated epithelial expression of 
the adenoviral trans-activating protein (E1A) in the airways 
of COPD subjects could also lead to reduced SLPI and elaﬁ  n 
expression, as shown by in vitro studies of E1A transfected 
lung epithelial cells where production of SLPI and elaﬁ  n is 
signiﬁ  cantly reduced (Higashimoto et al 2006).
Tissue inhibitors of metalloproteinases
Another crucial family of antiproteases are the tissue 
inhibitors of matrix metalloproteases (TIMPs). As their 
name suggests, this class of inhibitor targets the matrix 
metalloproteinases (MMPs) that are thought to be a central 
component of the pathogenesis of COPD, as discussed later. 
Studies of secretions from human subjects have shown 
that TIMP-1 is elevated in smokers and COPD subjects 
(Beeh et al 2003). Further in vitro studies utilizing primary 
epithelial cells cultured from healthy normal and COPD 
subjects, and ex vivo studies of tissue from a rat model 
of COPD, have immunolocalized TIMP-1 to the respira-
tory epithelium (Li et al 2002, 2005) and shown that it is 
elevated in COPD indicating that, under chronic inﬂ  amma-
tory conditions where proteases are elevated, the epithelium 
may act to regulate localized proteolytic activity in order 
to protect itself. This may also reﬂ  ect elevated epithelial 
MMP production and co-release of TIMP, as described 
previously (Tetley 2005)
Inactivation of antiprotease activity
Oxidation of the methionine residue at the reactive site of 
alpha 1-antitrypsin, SLPI and elaﬁ  n interferes with their 
inhibitory activity (Taggart et al 2000; Tetley 2006). Although 
this is an important “switch” to modulate antiprotease activity 
as necessary, for example to allow pericellular proteolysis, 
excessive oxidative inactivation of pulmonary serine protease 
inhibitors due to cigarette smoke exposure or via release of 
high levels of cellular oxidative free radicals could result 
in a reduced antiprotease screen and increased proteolytic 
load, rendering the lung susceptible to the consequences of 
excessive proteolytic activity, which triggers tissue injury 
and exacerbates inﬂ  ammation (Tetley 2006). Oxidative stress 
may also play an important role in modulating the activity 
of TIMPs in the lung. In vitro studies utilizing recombinant 
TIMP-1 have shown that peroxynitrite (ONOO-), an oxidant 
generated by the interaction of superoxide (O2
.-) with nitric 
oxide (NO), is able to inactivate TIMP-1 in a dose dependent 
manner (Frears et al 1996), possibly through disruption of 
the disulphide bonds that hold TIMP-1 in its complex tertiary 
structure. Similar studies have also shown that products of the 
nitric oxide pathway can degrade TIMP-1 activity in cultures 
of stromal ﬁ  broblasts (Brown et al 2004).
In addition to oxidative regulation of antiproteases, 
numerous studies have shown that proteases themselves 
may be able to cross-regulate inhibitors of other classes of 
protease (Tetley 2005). Okada and colleagues have shown 
that serine proteases are able to degrade TIMP-1, resulting in 
inactivation of their antiprotease activity (Okada et al 1988), 
whilst MMPs and cysteine proteases, such as the cathepsins, 
have been shown to degrade and inactivate serine protease 
inhibitors (Johnson et al 1986; Desrochers et al 1991; Liu 
et al 2000; Taggart et al 2001; Nie and Pei 2004).
Proteases
There is a considerable amount of evidence that inﬁ  ltrating 
phagocytic leukocytes, namely neutrophils and macrophages, 
contribute to increased proteolytic load in the lungs of smok-
ers and both these cell types secrete a broad spectrum of 
enzymes, including serine proteases (neutrophil elastase, pro-
teinase 3, cathepsin G) (Tetley 2005; Pham 2006), cysteine 
proteases (Cathepsins B, H, L, K and S) (Chapman et al 1997; 
Tetley 2005), and a range of MMPs, into the lungs of smok-
ers (Russell et al 2002; Tetley 2002; Vernooy et al 2004). 
Evidence that epithelial-derived proteases might contribute 
to the increased proteolytic load is more recent.
Matrix metalloproteinases in COPD 
and inﬂ  ammation
We now know that the pulmonary epithelium is a rich source 
of MMPs. These are perhaps the largest family of proteases 
implicated in the pathogenesis of COPD with over 25 mem-
bers identiﬁ  ed. Collectively, this family of enzymes is able 
to degrade all components of the extracellular matrix and 
was originally broadly classiﬁ  ed on the basis of substrate 
speciﬁ  city. Thus, MMP-1, -8 and -13 are collagenolytic, 
MMP-2 and -9 are gelatinolytic, MMP-3, -10 and -11 are 
stromelysins, while MMP-7 and -12 are elastinolytic. In 
addition there are membrane type MMP’s (MT-MMPs, 
MMP-14, -15, -16 and -17) which are anchored to the surface 
membrane of cells which can orchestrate the activity of other 
MMPs, for example MMP-14 cleaves, and activates, latent 
pro-MMP-2 in the vicinity of the cell.International Journal of COPD 2007:2(4) 415
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Immunohistochemical studies have shown that MMP-1 
and MMP-2 are up-regulated in the AT2 epithelial cells of 
COPD subjects and in vitro studies suggest that this increase in 
expression may be due to cigarette smoke activating mitogen-
activated protein kinases (MAPK) and subsequent up-regula-
tion of the MMP gene promoter region (Segura-Valdez et al 
2000; Mercer et al 2006). Furthermore, studies using both 
primary and immortal human bronchial epithelial cells have 
shown that cigarette smoke exposure stimulates MMP-9 and 
MMP-12 expression (Han et al 2003; Lavigne and Eppihimer 
2005). Increased epithelial cell MMP expression following 
cigarette smoke exposure may reﬂ  ect the known role of MMPs 
in repair and remodeling; clearly very important in an acute 
situation but, in a chronic situation, increased epithelial MMP 
synthesis and release is likely to contribute to tissue pathol-
ogy. Another sub-group of MMPs synthesized by pulmonary 
epithelial cells, known as the ADAMs (A Disintegrin and 
Metalloproteinase) family, have recently emerged and are 
being implicated in a number of diseases. Recent studies 
showing an association of ADAM 33 with bronchial hyper-
reactivity in asthmatics (Van et al 2002) have been extended 
to subjects with COPD where there is a close linkage between 
this molecule and airway inﬂ  ammation in the lungs of COPD 
subject (Gosman et al 2007). The exact role of this family of 
metalloproteinases, however, is yet to be fully understood.
MMPs can also regulate cytokine and chemokine activity. 
MMP-2 and MMP-9 have both pro- and anti-inﬂ  ammatory 
effects. For example, considering chemokines (classified 
below), MMP-2 can generate a truncated anti-inﬂ  ammatory 
form of CCL7 (MCP-3) from the pro-inﬂ  ammatory form, while 
MMP-9 can inactivate CXCL1 (GRO-α). Conversely, MMP-9 
can generate a truncated form of CXCL8 that is ten times more 
active than the parent molecule (Van den Steen et al 2000). 
Cytokines that are proteolytically processed and activated by 
MMP-9 include membrane-bound TNF-α (Gearing et al 1994) 
and transforming growth factor-β (TGF-β) (Yu and Stamenkovic 
2000). Furthermore both MMP-2 and MMP-9 proteolytically 
activate latent, pro-IL-1β (Schonbeck et al 1998). MMP-1 inacti-
vation of the chemokines, CCL2, -8 and -13 (MCP-1, -2 and -4) 
generates cleaved forms that bind to the MCP receptors CCR-2 
and -3 without eliciting leukocyte migration, thereby acting as 
endogenous inhibitors (McQuibban et al 2002).
Epithelial cathepsins
Epithelial cells from the bronchial and alveolar regions also 
secrete cathepsins K, L and H (Buhling et al 2004). This class 
of proteases has been shown to be potent in its ability to degrade 
collagen and elastin (Cardozo et al 1992; Novinec et al 2007), 
as well as inactivating SLPI and α1-antitrypsin as described 
above. Very little is known of the role of epithelial cell-derived 
cathepsins in smoking. However, macrophages from smokers 
demonstrate elevated levels of a number of cathepsins including 
cathepsins K, L and H (Reilly et al 1991; Takahashi et al 1993). 
It is therefore possible that cigarette smoke also modulates 
the synthesis and release of epithelial cathepsins, but to our 
knowledge this has not yet been described.
Epithelial integrity and repair
An important event in the development of emphysema is loss 
of the alveolar structure leading to enlarged alveoli and reduced 
surface area. In small airways disease there is also a signiﬁ  cant 
amount of remodeling. The initial damage is likely to be a 
combination of factors, including the direct effects of cigarette 
smoke as well as the effects of locally produced mediators. 
Whilst detrimental in itself, disruption of the epithelial layer 
without adequate repair will enhance the likelihood of expo-
sure of the extracellular matrix and interstitial cells to external 
agents eg cigarette smoke, particles, micro-organisms as well 
as locally produced mediators such as oxidants, cytokines, 
chemokines and proteases described above which may have 
detrimental effects on normal repair processes.
Cell survival and death
Research into the exact mechanism by which cigarette 
smoke causes loss of the epithelial layer has generated 
a number of hypotheses. Exposure of human bronchial 
epithelial cells to cigarette smoke in vitro caused DNA 
damage but also stimulated synthesis of the DNA repair 
enzyme poly (ADP-ribose) polymerase (PARP). Thus, 
cells were able to recover from cigarette smoke-induced 
DNA damage and continued to proliferate with no signs 
of apoptosis or necrosis (Liu et al 2005); thus a defect in 
this repair mechanism may contribute to epithelial dam-
age in COPD. In contrast, other studies have shown that 
exposure of the A549 adenocarcinoma cell line to cigarette 
smoke can cause both apoptosis and necrosis. At low 
doses, cigarette smoke appeared to induce apoptosis via 
a caspase-independent pathway whereas at higher doses 
necrosis was initiated. Instigation of the apoptotic pathway 
was dependent on components of the volatile phase of the 
cigarette smoke and could be attenuated by antioxidants 
and aldehyde scavengers (Hoshino et al 2001) supporting 
a mechanistic role for oxidants. Similarly, another study 
of A549 cells showed that higher doses of cigarette smoke 
induced necrosis and in addition prevented apoptosis by 
inhibiting caspase-3 activation. However, in contrast to the International Journal of COPD 2007:2(4) 416
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previous study, there was no apoptosis detected at lower 
concentrations of cigarette smoke (Wickenden et al 2003). 
Other in vivo studies and studies using primary alveolar 
epithelial cells in vitro show that cigarette smoke induces 
senescence, a state of irreversible growth arrest (Tsuji et al 
2004), a feature akin to the ageing process. Further studies 
by the same group conﬁ  rmed that epithelial senescence is 
an element of emphysema following investigation of lung 
tissue obtained from patients with emphysema, where they 
showed alveolar epithelial cell accumulation of senescence-
associated cyclin-dependent kinase inhibitors, p16INK4a and 
p21CIP1/WAF1/Sdi1 (Tsuji et al 2006). These studies suggest that 
there is a ﬁ  ne balance between the amount/concentration of 
cigarette smoke exposure and induction of cell death, which 
may also depend on the epithelial phenotype. Furthermore, 
alveolar epithelial cell senescence may contribute to the loss 
of tissue structure and function in emphysema.
Epithelial layer permeability
Another mechanism by which cigarette smoke can disrupt 
the integrity of the epithelial layer is by disrupting the tight 
junctions which tether cells together to form an imperme-
able barrier. These tight junctions, consisting of strands of 
claudin and occludin, are positioned near the apical surface 
and form a belt around the cell. Studies using gut epithelium 
have shown that the phosphorylation state of the tight junc-
tion proteins drastically affects their ability to maintain a 
tight barrier. Phosphorylation of occludin serine/threonine 
residues has been shown to increase tight junction integrity 
(Sakakibara 1997) whereas as phosphorylation of tyrosine 
residues is associated with increased permeability (Ward 
2002). In relation to the lung, Olivera and colleagues have 
investigated the effect of cigarette smoke on an airway cell 
line in vitro (Olivera et al 2007). In these studies it has been 
shown that, following exposure to cigarette smoke, there is 
a transient decrease in transepithelial resistance associated 
with increased macromolecular permeability. These changes 
in tight junction integrity were dependent on the activity 
of Rho kinase and protein tyrosine kinases, indicating that 
cigarette smoke affects airway permeability in a regulated 
manner and is not a purely cytotoxic response. In addition, Li 
and colleagues have demonstrated a role for antioxidants in 
regulation of epithelial cell permeability (Li et al 1994, 1996). 
Following instillation of cigarette smoke condensate in to rat 
lungs it was shown that increased epithelial cell permeability 
was associated with a concomitant decrease in glutathione 
levels. Further in vitro studies showed that the increase in 
epithelial permeability could be reversed by the addition of 
glutathione to the growth media, conﬁ  rming that oxidative 
mechanisms play a role in modulating permeability.
Role of vascular endothelial growth 
factor in epithelial repair
In addition to triggering cell death and increasing epithelial 
layer permeability, cigarette smoke interferes with cell repair 
mechanisms, further compounding its direct contribution to 
tissue damage during progression of COPD. In vitro studies of 
primary human and bovine bronchial epithelial cells showed 
that cigarette smoke extract inhibits a number of repair pro-
cesses, including chemotaxis, proliferation and extracellular 
matrix production, and this was shown to be dependent on 
the volatile components of the cigarette smoke (Lannan et al 
1994; Wang et al 2001). One mediator that may be central to 
epithelial repair in smokers is vascular endothelial growth fac-
tor (VEGF). As its name suggests this growth factor was once 
thought to be involved primarily in vascular growth. However, 
more recent studies have discovered that VEGF is expressed 
by a number of non-vascular cells and has properties that are 
important in tissue homeostasis (Voelkel et al 2006). In vitro 
studies using cell lines representing the bronchial and alveolar 
epithelium have shown that VEGF expression is increased in 
response to cigarette smoke exposure (Koyama et al 2002), 
while in studies comparing VEGF expression levels in COPD 
subjects and non-smokers, bronchiolar and alveolar epithe-
lial VEGF expression was found to be signiﬁ  cantly higher 
in COPD subjects compared to non-smokers (Kranenburg 
et al 2005) and this was inversely related to FEV1. Increased 
levels of epithelial VEGF in COPD lungs may simply reﬂ  ect 
the up-regulatory effects of cigarette smoke but may also be 
an attempt to repair damage to the epithelium and sub-epithe-
lium. However, and in contrast, in other studies of severely 
emphysematous tissue, disease severity was associated with a 
concomitant decrease in VEGF expression in the endothelial 
cells in the alveolar region. This decreased expression was also 
associated with reduced epithelial VEGF and increased alveo-
lar epithelial cell apoptosis (Kasahara et al 2001), possibly as 
a direct result of a reduction in the anti-apoptotic effects of 
VEGF. The latter study is supported by experimental animal 
investigations of genetic deletion of VEGF receptors-1 and -2 
(Tang et al 2004), where the animals developed emphysema, 
suggesting that VEGF is important in maintaining alveolar 
structure (Kasahara et al 2001). Decreased levels of VEGF in 
emphysematous regions of human lung associated with apop-
tosis may be as a result of the cigarette smoke overcoming the 
body’s defense mechanisms leading to loss of the very cells 
that produce VEGF. As well as being a pro-survival factor International Journal of COPD 2007:2(4) 417
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for the alveolar unit, VEGF may also play an important role 
in the clearance of apoptotic cells. Alveolar macrophages are 
known to express VEGF receptors and it has been shown that 
blockade of these receptors drastically reduces the ability of 
the macrophages to phagocytose apoptotic cells (Voelkel et al 
2006). Reduced VEGF may explain why there are increased 
numbers of apoptotic cells in the sputum of COPD subjects. 
Impaired clearance of these cells may further aggravate the 
situation, as apoptosis itself has been shown to stimulate VEGF 
release (Golpon et al 2004). Thus the exact role of epithelial 
cell-derived VEGF in COPD is unclear, although a signiﬁ  cant 
body of evidence suggests that reduced VEGF contributes to 
development of emphysema (Voelkel et al 2006). It seems 
likely that epithelial cell-derived VEGF exhibits differential 
activity at different levels of the respiratory tract and at dif-
ferent stages of the disease process.
Bacterial triggers of epithelial 
responses in COPD
Sources of bacterial products
A number of studies have shown that, in addition to the 
potential inﬂ  ammatory stimulus of the oxidative compo-
nents of cigarette smoke, it is a source of bacterial products, 
notably, endotoxin. Approximately 1% of the total endotoxin 
content of a cigarette can survive combustion and be detected 
in smoke generated from a lit cigarette. Despite being such 
a low proportion of the total endotoxin present in the unlit 
cigarette it has been concluded that the smoke inhaled from 
smoking one pack of cigarettes contains as much active 
endotoxin as that found to cause adverse health effects in 
cotton textile workers (Hasday et al 1999). It is not only the 
ﬁ  ltered, inhaled smoke that may have a deleterious effect on 
the health of smokers. The quality of indoor air from a room 
in which cigarettes have been smoked contains 120-fold more 
endotoxin compared to a room in which no cigarettes have 
been smoked (Larsson 2004). In addition, it is estimated that 
approximately 50% of all subjects with COPD have a per-
sistent colonization of the lower respiratory tract by bacteria 
such as Streptococcus pneumoniae,Haemophilus infuenzae 
and Moraxella catarhallis (Zalacain et al 1999), which are 
often associated with periods of exacerbation leading to an 
accelerated decline in lung function.
Role of Toll-like receptor-4 activation
LPS exerts its effect through Toll-like receptor-4 (TLR-4) 
a member of a superfamily of pattern recognition receptors 
(PRR). PRRs are activated by speciﬁ  c pathogen-associated 
molecular patterns (PAMP); thus, activation of TLR-4 and 
subsequent downstream signaling ultimately leads to transcrip-
tion of a number of genes involved in host defense (Figure 2). 
Amongst these are genes for chemokines, cytokines and 
major histocompatibility complex (MHC). TLRs, whilst 
being selective for their ligand of activation, share a number 
of similar intracellular signaling pathways, as well as having
speciﬁ  c pathways of their own. Signaling of these path-
ways leads to activation of the transcription factors NF-κB 
and AP-1, via phosphatidylinositol 3-kinase (PI3-K) and 
MAPKs (Akira and Takeda 2004). TLR4 has been located 
to bronchial epithelium from a number of species (Wassef 
et al 2004) including healthy human lung, being reduced in 
cystic ﬁ  brosis (Hauber et al 2005). LPS induces expression 
of TLR4 in bronchial epithelium of rat lung (Janardhan 
et al 2006) and TLR4 mRNA expression is increased in the 
bronchial epithelium from horses with airﬂ  ow obstruction 
(Berndt et al 2007). To our knowledge there are as yet no 
similar studies of human lung tissue.
Previous studies by us demonstrated human AT2 epithelial 
cell expression of TLR-4 (Armstrong et al 2004). Following 
treatment with LPS, AT2 cells released a broad spectrum of 
cytokines and chemokines including IL-1β, TNF-α, IL-6, 
CCL2, CXCL8, CXCL1 and CCL20 (MIP-3α) (Thorley et al 
2005, 2007). In addition, release of chemokines from AT2 
cells was far greater than that observed by alveolar macro-
phages from the same subjects under the same conditions of 
LPS exposure. The possible central role of TLR4 activation 
of AT2 cells in alveolar chemokine release has been further 
supported by in vivo studies in mice which found that, follow-
ing LPS, the AT2 cell is a predominant source of neutrophil 
chemoattractant chemokines, dependent upon TLR4 signaling 
mechanisms (Jeyaseelan et al 2005).
Newly emerging studies are showing that TLRs may 
also be able to respond to exogenous stimuli other than those 
from microbial sources such as cigarette smoke as well as 
endogenous ligands generated during inﬂ  ammation, such as 
necrotic cells, heat shock proteins and β-defensins (Tobias 
and Curtiss 2005). A recent study using human monocyte 
derived macrophages showed that cigarette smoke expo-
sure stimulated a number of cytokines, including CXCL8. 
This was mediated via TLR-4 and was independent of any 
LPS there may have been in the cigarette smoke (Karimi 
et al 2006). In addition, animal studies have shown that 
TLR-4 defective mice have an impaired response to ciga-
rette smoke exposure, with signiﬁ  cantly less inﬁ  ltrating 
leukocytes observed and lower levels of cytokines and 
chemokines in the BAL (Maes et al 2006). In addition, loss International Journal of COPD 2007:2(4) 418
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of TLR4 expression (TLR4 deﬁ  ciency) causes emphysema 
over time in mice; this was ascribed to increased NADPH 
oxidase activity leading to oxidative stress and increased 
elastolytic activity (Zhang et al 2006). These studies suggest 
that in COPD, TLR4 signaling is important in the inﬂ  am-
matory process and abnormalities may contribute to loss 
of lung structural integrity.
Role of Toll-like receptor-2 activation
In addition to expressing TLR-4, studies by us (Armstrong 
et al 2004) and preliminary unpublished research carried 
out in our laboratory have shown that human AT2 epithelial 
cells express mRNA for TLR-2 and respond to treatment 
with TLR-2 speciﬁ  c ligands by releasing a broad spectrum 
of cytokines and chemokines. TLR-2 recognises a number of 
microbial products such as peptidoglycan from Gram-positive 
bacteria, bacterial lipoproteins, lipoarabinomannan from 
mycobacteria and yeast cell walls. Its broad range of ligand 
speciﬁ  city may be accountable to its ability to heterodimerise 
with two other TLRs, TLR-1 (Wyllie et al 2000) and TLR-
6 (Takeuchi et al 2001) (Figure 2). This group of TLRs 
may play a critical role in the inﬂ  ammatory response of the 
COPD lung as one of the most common infections in COPD 
subjects is Moraxella Catarrhalis, a Gram-positive bacteria. 
It is also possible that TLR-2-active ligands are present in 
tobacco smoke in a similar fashion to LPS; however, no 
studies have as yet addressed this. Investigations of a vari-
ety of epithelial cells, both primary and immortal, from the 
bronchial and alveolar regions have shown that TLR-2 is 
expressed throughout the respiratory tract (Droemann et al 
2003; Mayer et al 2007; Slevogt et al 2007) and is rapidly 
up-regulated following exposure to microbial products (Saito 
Figure 2  Signaling pathways initiated by TLR-2 and TLR-4 activation. Upon ligation of the TLR-4 receptor complex by exogenous (eg, LPS) or endogenous 
(eg, hyaluronic acid and β-defensin 2) ligands, MyD88-dependent and MyD88-independent signaling pathways are initiated leading to activation of the tran-
scription factors NF-κB and IRF3. TLR-2 heterodimerises with either TLR-1 or -6 in order to recognise distinct groups of exogenous ligands and signal through 
a MyD88-dependent pathway. TLR-1/2 recognizes triacyalted (TriAc) lipoproteins and lipoarabinomannan whereas TLR-2/6 recognizes diacylated (DiAc) 
lipoproteins, lipoteichoic acid and zymosan. TLR-2 may also initiate responses to endogenous products released by necrotic cells.International Journal of COPD 2007:2(4) 419
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et al 2005). Following stimulation with TLR-2 ligands, air-
way epithelial cells also release a similar proﬁ  le of mediators 
to those discussed earlier with respect to LPS (Hertz et al 
2003; Ritter et al 2005; Schmeck et al 2006). This may be 
explained by further studies that have shown that, whilst the 
accessory proteins associated with the two classes of receptor 
may differ, ultimately, they activate the same transcription 
factors (Trinchieri and Sher 2007). Preliminary work by us 
shows that human alveolar epithelial cells express a range of 
TLRs. The role of TLRs in the pathogenesis of COPD is an 
active area of research and the precise role, if any, of each 
TLR remains to be established.
Cytokines and chemokines
Interleukin-1β and tumor necrosis factor-α
As mentioned above, activation of PRRs initiates synthesis 
and release of a variety of mediators including cytokines and 
chemokines. There is now good evidence that these recep-
tors can also be activated by endogenous and other ligands 
such as β-defensin-2, heat shock proteins, components of 
hyaluronic acid and ﬁ  brinogen, heparin sulfate and oxidative 
stress (Tobias and Curtiss 2005); such processes could be 
highly relevant in COPD, which develops in an environment 
of continual exposure to oxidants and tissue remodeling, and 
these factors may contribute to the continued cycle of inﬂ  am-
mation that takes place even after cessation from smoking. 
Furthermore, once released, mediators such as cytokines and 
chemokines can perpetuate the inﬂ  ammatory response.
A number of cytokines and chemokines have been impli-
cated in the pathogenesis of COPD (Table 1.). Amongst the 
most actively investigated cytokines are the early response 
cytokines IL-1β and TNF-α. Studies of sputum and cultures 
of primary bronchial epithelial cells from COPD subjects 
have shown that both of these cytokines are present in 
high concentrations compared to non-smokers (Keatings 
et al 1996), (Rusznak et al 2000). The interleukin-1 (IL-1) 
superfamily consists of two agonists, IL-1α and β, and one 
antagonist, IL-1 receptor antagonist (IL-1Ra). IL-1α is 
predominantly found tethered to the cell surface whereas 
as IL-1β is found in a soluble secreted form. Both isotypes 
are secreted by a wide variety of cells, including pulmonary 
epithelial cells, and exert their actions through the same IL-1 
type I receptor to elicit similar responses (Dinarello 1998). 
TNF-α exists in a transmembrane form that is activated into 
its soluble form by tumor necrosis factor (TNF)-converting 
enzyme (TACE). Evidence suggests that TNF-α is a crucial 
mediator of the pathogenesis of COPD (Churg et al 2002, 
2003). Like IL-1, it is produced by a wide variety of lung 
cells (Ziegenhagen et al 1997; Noda et al 2003; Proﬁ  ta et al 
2003) in response to a broad spectrum of insults (Driscoll 
et al 1995; Churg et al 2002; Ermert et al 2003). In the 
case of infection/exacerbation it is believed that the pro-
inﬂ  ammatory response is not only as a result of the direct 
activity of endotoxin itself but also of the primary cytokines 
that are subsequently released. Thus, LPS-induction of 
primary human AT2 cell release of CCL-2 over 24 hours 
was dependent on the autocrine effects of LPS-induced 
IL-1 and TNF-α release (Thorley et al 2007). Exposure 
of primary human bronchial epithelial cells from healthy 
non-smokers, healthy smokers and smokers with COPD 
to gaseous cigarette smoke caused increased IL-1 release 
from COPD cells compared to healthy smokers’ cells; the 
cigarette smoke also induced a marked reduction in cel-
lular GSH, which was suggested to exacerbate IL-1 release 
(Rusznak et al 2000). Furthermore, cigarette smoke extract 
stimulated both IL-1 and TNF-α secretion by primary human 
small airway epithelial cells, at least partly via induction of 
the early growth response gene (Egr-1), a hypoxia-sensi-
tive gene that is highly expressed in the lungs of smokers 
with COPD (Reynolds et al 2006). As these cytokines have 
marked effects on all inﬂ  ammatory and structural lung cells, 
stimulating production of a myriad of mediators, release of 
these cytokines by pulmonary epithelium, one of the ﬁ  rst 
cellular targets, following induction by cigarette smoke is 
likely to be an important contributory mechanism to the 
development of COPD in susceptible subjects.
Interleukin-6
IL-6 has also been shown to be elevated in the secretions of 
COPD subjects although its role in COPD remains unclear 
due to its pleiotropic effects. A variety of cells including 
alveolar epithelial cells, alveolar macrophages, ﬁ  broblasts 
and endothelial cells are capable of producing IL-6 (Sad et al 
1995; Koyama et al 1998; Frampton et al 1999; Arcangeli et al 
2001; Yu et al 2002). Whilst the pro-inﬂ  ammatory effects of 
IL-6 are widely known, its anti-inﬂ  ammatory activity is often 
disregarded. Although it induces expression of many pro-
inﬂ  ammatory mediators in a similar way to TNF-α and IL-1, 
it does not up-regulate mediators of inﬂ  ammation such as the 
prostaglandins and matrix metalloproteinases. Furthermore, 
LPS-induced IL-6 can inhibit the release of IL-1 and TNF-α, 
following LPS exposure, by autocrine, feed back mechanisms. 
It is suggested that IL-6 has a modulatory mechanism that 
dampens the acute-phase response, preventing development of 
a chronic inﬂ  ammatory state (Barton 1997). Bronchiolar and International Journal of COPD 2007:2(4) 420
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alveolar epithelial cell division/repair was reduced in cigarette 
smoke exposed IL-6 knock out mice compared to WT controls, 
suggesting that IL-6 is important in the repair of epithelial dam-
age following acute injury. Interestingly, exposure of human 
small airway epithelial cells to cigarette smoke induces IL-6 
release (Kode et al 2006) and is important in preventing DNA 
damage and cell death on exposure to low levels of cigarette 
smoke (Yu et al 2002). The evidence suggests that this is due to 
the autocrine activity of IL-6 which activates signal transducer 
and activator of transcription 3 (STAT3), a transcription factor 
that has been shown to be important in cell proliferation, dif-
ferentiation, apoptosis, inﬂ  ammation and wound repair. Thus 
cigarette smoke-induced IL-6 release by epithelial cells may be 
a signiﬁ  cant anti-inﬂ  ammatory and repair mechanism.
Chemokines: monocyte and neutrophil 
recruitment
Recruitment of different classes of leukocytes is controlled 
by distinct groups of chemokines. CXC chemokines contain-
ing the ELR amino acid motif, such as CXCL8 and CXCL1, 
are traditionally considered to be the primary chemokines 
responsible for recruitment of neutrophils, although there 
is evidence that they also have chemotactic activity for 
monocytic cells. The CC chemokines, such as CCL2, CCL4 
(Macrophage Inﬂ  ammatory Protein-1β; MIP-1β) and CCL5 
(Regulated Upon Activation Normal T cells Expressed and 
Secreted; RANTES) are also elevated following infection 
and during pulmonary inﬂ  ammatory disorders and are key 
to the recruitment of mononuclear cells. Both CXC and 
CC chemokines are elevated in COPD (Barnes 2004). In 
studies of induced sputum from COPD subjects, CCL2 
and CXCL1 levels were found to be elevated (Traves et al 
2002) as is CXCL8 (Pesci et al 1998), which is further 
elevated during periods of exacerbation (Aaron et al 2001). 
These chemokines are likely to be derived from a number 
of cellular sources and there has been much emphasis on the 
macrophage in this process. However, examination of human 
lung tissue highlights the epithelium as a signiﬁ  cant source. 
For example, de Boer and colleagues discovered that CCL2 
and CXCL8 mRNA and protein expression was signiﬁ  cantly 
higher in bronchiolar epithelium from ex-smokers with 
COPD compared to ex-smokers without COPD (de Boer et al 
2000). Subsequent studies (Fuke et al 2004) using laser-
capture microdissection techniques conﬁ  rmed this ﬁ  nding 
with CXCL8 and CCL2 and, in addition, showed that CCL3 
(MIP-1α) mRNA expression was higher in bronchiolar 
epithelium from smokers with airﬂ  ow limitation and/or 
emphysema compared to smokers without these conditions 
and never smokers; furthermore, there were no differences 
between any of these subject groups in macrophage che-
mokine expression. This latter observation is interesting in 
light of the aforementioned investigation of human alveolar 
epithelial cells and macrophages isolated from the same sub-
jects where the epithelial cells were demonstrated to secrete 
signiﬁ  cantly higher levels of chemokines in response to LPS 
exposure under identical conditions (Thorley et al 2007)), 
supporting the concept that the epithelium quantitatively 
and qualitatively modulates leukocyte trafﬁ  cking, possibly 
under the inﬂ  uence of cytokine release by macrophages. In 
vitro studies have also shown that epithelial cells secrete 
CXCL8 (DeForge et al 1993; Kode et al 2006; Thorley et al 
2007) and CXCL1 (Schulz et al 2004; Thorley et al 2007) in 
response to a number of mediators associated with smoking 
and COPD eg pro-inﬂ  ammatory cytokines, bacterial prod-
ucts, oxidative stress and cigarette smoke extract. Cigarette 
smoke stimulation of primary human bronchial epithelial cell 
CXCL8 mRNA expression and protein secretion has been 
attributed to various components of tobacco smoke, including 
acrolein, acetaldehyde (Mio et al 1997) and nicotine (Tsai 
et al 2006), while oxidative stress triggers CXCL8 release by 
Table 1  Cytokines and chemokines implicated in the pathogenesis of COPD
Cytokine Up/Down  Regulated  References
IL-1β  ↑  (Kuschner et al 1996; Dignetti 2002) 
IL-6  ↑  (Kuschner et al 1996; Bucchioni et al 2003)
IL-10  ↓  (Takanashi et al 1999)
TNF-α  ↑↑  (Keatings et al 1996; Soler et al 1999)
CCL2 (MCP-1)  ↑↑  (Kuschner et al 1996; Traves et al 2002)
CCL3 (MIP-1α)  ↑  (Fuke et al 2004)
CCL5 (RANTES)  ↑  (Zhu et al 2001; Fujimoto et al 2005)
CCL20 (MIP-3α)  ↑↑  (Bracke et al 2006; Demedts 2007)
CXCL1 (GROα)  ↑↑  (Morrison et al 1998;Traves et al 2002)
CXCL8 (IL-8)  ↑↑↑  (Keatings et al 1996; Kuschner et al 1996;  
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small airway epithelial cells (Kode et al 2006). Up-regulation 
of the MAPK pathway in human bronchial epithelial cells by 
nicotine, through extracellular signal-related kinase 1 / 2 and 
c-Jun-NH(2)-terminal kinase, but not p38 MAPK signaling 
(Tsai et al 2006), and increased levels of the transcription 
factor, NF-κB, have been observed (Kode et al 2006). In 
contrast, other in vitro studies of the effects of cigarette 
smoke on CXCL8, CXCL1 and CCL2 release by primary 
human AT2 cells suggest that it is inhibitory, due to oxida-
tive stress; this could be due to inhibition of the transcription 
factor, AP-1 (Laan et al 2004). Differences between studies 
will reﬂ  ect the source of epithelial cells (eg primary or cell 
lines) (Witherden et al 2004; Kode et al 2006) as well as the 
region of the respiratory tract from which they were isolated. 
Unlike the stimulatory effects of cigarette smoke that occur 
with large airway epithelial cells, subjugation of alveolar 
epithelial responses by cigarette smoke may contribute to 
emphysema due to inadequate inﬂ  ammatory response and 
reduced repair. A counterbalance to this in COPD subjects 
could be the observed increased sensitivity/capacity of 
pulmonary epithelium from COPD subjects, compared to 
subjects with normal lung function, to secrete CXC chemo-
kines in response to TNF-α (Patel et al 2003; Schulz et al 
2004); thus, TNF-α release by stimulated inﬂ  ammatory 
macrophages (Thorley et al 2007) could activate COPD 
airway epithelium to release pathologically relevant quanti-
ties of chemokines.
Chemokines: dendritic cell recruitment
Pulmonary epithelial cells are also a rich source of CCL20 
(Reibman et al 2003; Thorley et al 2005), which is a potent 
dendritic cell chemokine. Human bronchial epithelial cells 
release CCL20 in response to cytokines (TNF-α, IL1-β, IL-4, 
IL-13), environmental particulate matter and diesel exhaust 
particles (Reibman et al 2003), while LPS stimulates human 
AT2 cells, but not macrophages, to release CCL20 (Thorley 
et al 2005). Furthermore, while exposure of dendritic cells 
to diesel exhaust failed to stimulate phenotypic or functional 
maturation, when dendritic cells were co-incubated with 
diesel exhaust-exposed human bronchial epithelial cells, or 
conditioned media from these cells, they underwent both 
phenotypic and functional maturation (Bleck et al 2006). 
Epithelial cell-derived granulocyte-macrophage colony 
stimulating factor was found to be important in this process. 
Of particular signiﬁ  cance to COPD is the recent discovery 
that Langerhans positive dendritic cells accumulate in the 
airways of lung tissue from COPD subjects and this increases 
with the severity of the disease (Demedts et al 2007). In 
parallel studies of CCL20 mRNA in total lung and CCL20 
protein in induced sputum, there was again an increase in the 
COPD samples; interestingly, CCL20 levels were inversely 
correlated with FEV1. Furthermore, when freshly isolated 
pulmonary dendritic cells were examined for CCR6, the 
receptor for CCL20, myeloid dendritic cells expressed this 
receptor, suggesting that myeloid dendritic cell recruitment is 
orchestrated via epithelial release of CCL20. In this respect, 
unpublished studies by us show that cigarette smoke induces 
CCL20 release by primary human AT2 cells, directly linking 
CCL20-induced dendritic cell recruitment to the stimulatory 
effect of cigarette smoke on epithelial cells.
Mucus and surfactant
The airway surface ﬂ  uid overlying the ciliated epithelium is 
composed of a periciliary ﬂ  uid layer in which the cilia reside, 
and a mucus layer which lies on top of this. The respiratory 
mucus is comprised of a mixture of salts, protein, glycoprotein 
and water and is derived from the secretions of cells from sev-
eral areas including the alveolus (Danahay and Jackson 2005). 
In the peripheral and alveolar regions of the lung, the epithelium 
is covered by a thin ﬁ  lm of surfactant, a complex mixture of 
phospholipids and proteins secreted by a number of different 
cells (Frerking et al 2001). As such, the lung lining ﬂ  uid is one 
of the ﬁ  rst points of contact for inhaled matter and studies have 
shown that it is more than just a physical barrier.
Mucin
As well as keeping the epithelial layer hydrated and the air-
ways humidiﬁ  ed, respiratory mucus acts as a ﬁ  ltration barrier 
for the airway surface ﬂ  uid and is essential to local defense. 
Inhaled particles adhere to the mucus layer due to its complex 
glycoprotein structure and once embedded within the mucus 
layer are cleared by the mucociliary escalator (Girod et al 1992; 
Houtmeyers et al 1999). Their production can be induced by 
a variety of pro-inﬂ  ammatory stimuli such as cigarette smoke 
and cytokines and hyperproduction of mucins plays a key part 
in the obstruction of the airways observed in COPD (Rogers 
2005). In vitro and in vivo studies have shown that cigarette 
smoke-induction of mucin secretion can synergize with bacte-
rial cell wall products to amplify mucin secretion (Baginski 
et al 2006). This has powerful implications in a disease such 
as COPD where as many 50% of subjects may have persistent 
bacterial colonization of the lung (Patel et al 2002).
How cigarette smoke induces mucin secretion appears to 
be dependent on its oxidative potential. Recent studies have 
shown that increased mucin secretion in the airways is closely 
related to activation of the epidermal growth factor recep-International Journal of COPD 2007:2(4) 422
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tor, a member of the ErbB family of receptors (Burgel and 
Nadel 2004). Using airway cell lines, Gensch and colleagues 
showed that expression of MUC5AC was up-regulated by 
cigarette smoke-induced EGF receptor- dependent and inde-
pendent activation of ERK and JNK which led to the activa-
tion of a smoke response transcription element upstream of 
the MUC5AC gene (Gensch et al 2004). This transcription 
element was shown to be dependent on the AP-1 JunD/Fra-2 
heterodimer for activation (Figure 3). Increased mucin secre-
tion may be caused by cigarette smoke-induced accumulation 
of MUC5AC mRNA which has been suggested to be due to 
enhanced/prolonged gene promoter activity. Furthermore, 
reactive oxygen species generated by NADPH oxidase in 
response to cigarette smoke are thought to activate the sig-
naling kinase Src which in turn activates TNF-α converting 
enzyme (TACE), a member of the ADAMs family. One of 
the targets of TACE activity is membrane bound TGF-α, a 
growth factor that is one of the main ligands for the EGF 
receptor (Shao et al 2004).
In addition to stimulating increased mucin release via 
activation of ErbB1 receptors, clinical studies of the ErbB3 
receptor show that it is up-regulated on mucin secreting cells 
in the airway epithelium of long term smokers (O’Donnell 
et al 2004). This has led to the hypothesis that this recep-
tor, too, may play a role in mucin expression, although its 
functional role has yet to be demonstrated.
Surfactant
As previously mentioned, surfactant is a mixture of lipids, 
mainly phospholipids (approximately 80%), and proteins 
(approximately 10%) secreted primarily by the AT2 cell 
and, to a lesser extent, Clara cells and bronchial submucosal 
Figure 3  Cigarette smoke-induced secretion of mucins. Mucin secretion is stimulated following cigarette smoke-induced activation of NADPH oxidase and TACE. NADPH 
oxidase generates intracellular reactive oxygen species leading to activation of the transcription factor AP-1. TACE cleaves pro-TGFα to generate the active ligand which 
initiates signaling through the ErbB receptor complex leading to activation of the transcription factors AP-1 and Sp1. Diagram a kind gift of Samir Nuseibeh.International Journal of COPD 2007:2(4) 423
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glands. As well as maintaining the patency of the alveolar 
unit, by maintaining reduced surface tension, a number 
of studies have demonstrated that surfactant also plays an 
important role in the host defense. Surfactant proteins A and 
D (SP-A and -D) bind to surface motifs on a wide variety 
of bacteria and act as opsonins, facilitating phagocytosis 
of bacteria by macrophages (Kabha et al 1997), as well as 
damaging the bacteria directly by disrupting the bacterial 
envelope (Wu et al 2003).
Studies investigating the effect of smoking on lung surfac-
tant have proved inconclusive. Early studies showed that total 
surfactant levels in bronchoalveolar lavage (BAL) ﬂ  uid were 
decreased (Finley and Ladman 1972) whereas later studies 
showed that there was no difference between non-smokers 
and healthy smokers (Low and 1978; Mancini et al 1993). The 
lower levels detected in the ﬁ  rst study, however, may have 
been due to the low BAL recovery volume. Measurement of 
speciﬁ  c surfactant proteins indicates that both SP-A and SP-D 
levels and activity are decreased in the lungs of smokers and 
subjects with COPD (Cook and Webb 1966; Schmekel et al 
1992; Honda et al 1996). Decreased levels of these important 
antimicrobial collectins could, in theory, render the lung 
vulnerable to bacterial colonization and may explain, in part, 
the observation of increased and persistent bacterial load in 
the lungs of COPD subjects (Sethi et al 2006). Very recent 
population studies have shown that a single nucleotide poly-
morphism (SNP) in the gene encoding SP-D is associated 
with development of COPD and a decline in forced expiratory 
volume in one second (FEV1). In addition, it was also shown 
that a SNP in SP-A was associated with the rate of decline in 
FEV1 within subjects with established COPD (van Diemen 
et al 2006). This is the ﬁ  rst study to show a genetic linkage 
between surfactant proteins and disease development. How-
ever, the relevance of these polymorphisms to the function of 
the proteins is unknown, but they are likely to be important 
in the development of COPD.
Figure 4  Role of the pulmonary epithelium in cigarette smoke-induced inﬂ  ammation. The pulmonary epithelium combats leukocyte-derived oxidants and free radicals in 
cigarette smoke via release of antioxidants. Serine proteases are blocked by low molecular weight inhibitors, SERPINS and TIMPs. Induction of cytokine release by macrophages 
and epithelial cells and autocrine/paracrine activation of the epithelium stimulates chemokine release and recruitment of monocytes, neutrophils and dendritic cells. In COPD 
the epithelial defense mechanisms are overwhelmed, leading to increased oxidative stress and proteolytic load, together with leukocyte recruitment, resulting in a chronic 
cycle of inﬂ  ammation that may be independent of cigarette smoke exposure.   International Journal of COPD 2007:2(4) 424
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Summary
This article aims to highlight the dynamic nature of the 
pulmonary epithelium in relation to cigarette smoke expo-
sure and the pathophysiology of COPD. We have focused 
on areas of particular interest to us. A ﬁ  rst line of defense 
against inhaled foreign organic and inorganic material, the 
epithelium is not only a tight structural membrane barrier 
but is also a potent metabolic powerhouse, communicating 
between the luminal, interstitial and vascular compartments 
(Figure 4). Here we have emphasized its protective role, for 
example, against noxious particles and chemicals, combat-
ing oxidative stress and excessive proteolytic activity. In 
addition, we have illustrated some aspects of the crucial role 
of the epithelium in modulating inﬂ  ammation, repair and 
remodeling of the lung. Cigarette smoke has an enormous 
impact on the epithelium; indeed, it is perhaps surprising 
that only a small proportion of smokers develop COPD. 
We suggest that one reason for this is that the pulmonary 
epithelium plays a central role countering many of the toxic 
effects of cigarette smoke to limit lung damage and maintain 
adequate lung function.
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